Oslo, Norway, 09 March 2026 - Zelluna (OSE: ZLNA), a company pioneering
allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell
therapies for the treatment of solid cancers, today announced a collaboration
with Etcembly Ltd, a biotechnology company applying advanced machine learning to
T cell receptor (TCR) discovery and engineering.

Highlights:

  * AI-enabled collaboration to engineer KKLC1-targeting TCRs for Zelluna's TCR-
    NK platform
  * Builds on successful engineering of MAGE-A4 TCR underpinning ZI-MA4-1,
    approved for clinical testing in February 2026
  * Expands pipeline with validated solid tumour antigen expressed across
    multiple difficult-to-treat cancers
  * AI-guided in silico engineering to enhance specificity, potency and
    development efficiency

The collaboration will focus on the engineering of high-affinity, tumour-
specific TCRs targeting KKLC1, a validated cancer antigen found in multiple
difficult-to-treat solid tumours. The engineered receptors will be fully owned
by Zelluna and developed for use within Zelluna's proprietary TCR-NK platform.
In-vitro data demonstrating safety, specificity and functional activity is now
expected in Q4 2026.

This collaboration builds on Zelluna's successful engineering of a T cell
receptor (TCR) designed to recognise the cancer antigen MAGE-A4. This receptor
is the targeting module of the company's lead product candidate ZI-MA4-1, which
in February 2026 received approval from the UK Medicines and Healthcare products
Regulatory Agency (UK MHRA) to initiate clinical testing. By engineering
receptors targeting KKLC1, Zelluna is expanding its product portfolio beyond
MAGE-A4 and can thereby address a broader spectrum of solid cancers and
patients.

"Our lead product candidate ZI-MA4-1 is built on an affinity enhanced receptor
that recognises cancer cells with the MAGE-A4 protein. We developed this
receptor in our first highly successful collaboration with Etcembly," said Luise
Weigand, Chief Scientific Officer of Zelluna. "We are now delighted to continue
our collaboration on our next programme targeting KKLC1. By combining artificial
intelligence with our cell therapy platform, we aim to develop highly precise
and potent treatments for solid cancers."

"Our first collaboration with Zelluna demonstrated what AI-guided TCR
engineering can achieve: a clinically approved receptor in a fraction of
conventional timelines. We are excited to apply EMLy(TM) again to expand
Zelluna's
pipeline and address cancers that desperately need new treatment options"
commented Michelle Teng, Founder and CEO of Etcembly.

About Etcembly's EMLy(TM) Platform:

Etcembly's proprietary platform, EMLy(TM), uses artificial intelligence and
machine
learning to analyse large amounts of data on immune receptors. This enables the
design and engineering of optimised T cell receptors (TCRs) through
computational modelling before they are tested in the laboratory. Rather than
only testing many candidates in the laboratory, the platform can predict how the
receptors will function and thereby improve precision, increase potency and
reduce the risk of unintended effects. This AI-driven approach increases both
precision and efficiency in the development of tumour-specific receptors
suitable for cancer treatment.

About Zelluna's TCR-NK Platform:

Zelluna's TCR-NK platform combines the precise tumour recognition capabilities
of T cell receptors with the innate, multi-mechanism cytotoxicity of Natural
Killer (NK) cells in an allogeneic, off-the-shelf format designed for
scalability and patient access. By expanding its target portfolio to include
KKLC1, Zelluna continues to build a diversified pipeline aimed at addressing a
broad range of cancers and broad reach of cancer patients.

Definitions:

TCR (T Cell Receptor): A protein on the surface of T cells that recognises
specific antigens on cancer cells. TCRs provide precise targeting of cancer
cells.

NK cells (Natural Killer cells): Immune cells with innate ability to kill cancer
cells through multiple mechanisms, without the need for prior activation.

TCR-NK: Zelluna's proprietary technology that combines the precise targeting of
TCRs with the potent killing ability of NK cells.

KKLC1: A cancer antigen (protein) expressed in multiple difficult-to-treat solid
cancers, representing a validated target for cancer treatment.

MAGE-A4: A cancer antigen found in many solid cancers, including lung, ovarian,
head and neck cancers and sarcomas. The target for Zelluna's lead product
candidate ZI-MA4-1.

In silico: Performed using computational modelling and simulation, as opposed to
laboratory experiments.

In vitro: Experiments performed in the laboratory, outside a living organism.

About Zelluna ASA

Zelluna ASA (OSE: ZLNA) is a pioneering allogeneic 'off-the-shelf' T Cell
Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers.
The company's platform combines the innate killing power of NK cells with
precise solid tumour targeting of TCRs, designed to address the limitations of
current cell therapies in solid tumours. The company's lead candidate, ZI-MA4-
1, is the world's first MAGE-A4 targeting TCR-NK therapy. Zelluna received
approval for its Clinical Trial Application from the UK MHRA in February 2026,
with initial clinical data expected to emerge from mid-2026. Zelluna is
headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway and is
listed on the Oslo Stock Exchange under the ticker ZLNA.

About Etcembly

Etcembly is pioneering a new frontier in immune repertoire analysis, where
cutting-edge computational technologies converge with the transformative power
of large language models (LLMs) to accelerate the discovery and engineering of
safe and efficacious immunotherapies. Through its proprietary AI platform,
EMLy(TM), the company integrates powerful machine learning techniques with deep
immunological expertise to decode, predict, and design high-performance
biologics at unprecedented speed. Etcembly's mission is to redefine the
landscape of AI-guided drug research by offering innovative tools and solutions,
ultimately paving the way for next-generation immunotherapies.

For further information, please contact:

Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com (mailto:namir.hassan@zelluna.com)
Phone: +44 7720 687608